[关键词]
[摘要]
目的：探讨23G微创玻璃体切割联合术治疗增生性糖尿病视网膜病变(proliferative diabetic retinopathy，PDR)的安全性及有效性。
方法：对40例40眼纤维血管膜范围>5PD增生性糖尿病视网膜病变患者随机行20G及23G玻璃体切割联合术治疗，回顾上述患者的病历资料。对术后视力、眼内压、术中及术后并发症等情况进行分析。
结果：23G组手术后1，3，6mo的最佳矫正视力为LogMAR(0.88±0.43)、(0.69±0.23)、(0.45±0.17)，20G组手术后1，3，6mo的最佳矫正视力为LogMAR(0.57±0.32)，(0.41±0.21)，(0.30±0.17)，两组比较差异无统计学意义。随访时间为6～23mo。
结论：23G玻璃体切割联合术是治疗复杂增生性糖尿病视网膜病变的安全有效方法。
[Key word]
[Abstract]
AIM: To evaluate the safety and effectiveness of 23G micro-invasion vitrectomy combined surgery for proliferative diabetic retinopathy(PDR).
METHODS: Forty cases(40 eyes)with PDR of fibrovascular membrane range >5PD were randomly treated with 20G and 23G vitrectomy combined surgery. The medical records of patients were reviewed, and the visual acuity of postoperation, intraocular pressure, complications in preoperation or postoperation were analyzed.
RESULTS:After 1, 3 and 6mo of surgery, the best corrected visual acuity(BCVA)were LogMAR(0.88±0.43),(0.69±0.23),(0.45±0.17)in group 23G, and LogMAR(0.57±0.32),(0.41±0.21),(0.30±0.17)in group 20G. Compared with each other, the differences were not statistically significant. The patients were followed up 6-23mo after surgery.
CONCLUSION: 23G vitrectomy issafe and effective for complicated PDR.
[中图分类号]
[基金项目]
中国广东省肇庆市科技局基金资助项目(No.2013E161)
